These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 16373540)

  • 21. Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences.
    Horiike N; Duong TN; Michitaka K; Joko K; Hiasa Y; Konishi I; Yano M; Onji M
    J Med Virol; 2007 Jul; 79(7):911-8. PubMed ID: 17516520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews.
    Hagen NA; Stiles C; Nekolaichuk C; Biondo P; Carlson LE; Fisher K; Fainsinger R
    J Pain Symptom Manage; 2008 Feb; 35(2):136-52. PubMed ID: 18178370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of ion-exchange column breakthrough curves by constant-pattern wave approach.
    Lee IH; Kuan YC; Chern JM
    J Hazard Mater; 2008 Mar; 152(1):241-9. PubMed ID: 17686577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breakthrough of the year. Breakdown of the year: scientific fraud.
    Couzin J
    Science; 2006 Dec; 314(5807):1853. PubMed ID: 17185568
    [No Abstract]   [Full Text] [Related]  

  • 25. The year 2008: a breakthrough year for health protection from climate change?
    Neira M; Bertollini R; Campbell-Lendrum D; Heymann DL
    Am J Prev Med; 2008 Nov; 35(5):424-5. PubMed ID: 18929967
    [No Abstract]   [Full Text] [Related]  

  • 26. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y; Taura K; Taguchi T; Furusu A; Kohno S
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.
    Lee CH; Kim SO; Byun KS; Moon MS; Kim EO; Yeon JE; Yoo W; Hong SP
    Gastroenterology; 2006 Apr; 130(4):1144-52. PubMed ID: 16618409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphorous retardation and breakthrough into well water in a soil-aquifer treatment (SAT) system used for large-scale wastewater reclamation.
    Lin C; Banin A
    Water Res; 2006 May; 40(8):1507-18. PubMed ID: 16616770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breakthrough of the year. The runners-up.
    Science; 2007 Dec; 318(5858):1844-9. PubMed ID: 18096772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A critical review of financial measures as reported in the Ontario hospital balanced scorecard.
    Parkinson J; Tsasis P; Porporato M
    J Health Care Finance; 2007; 34(2):48-56. PubMed ID: 18972993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The incidence and implications of aldosterone breakthrough.
    Bomback AS; Klemmer PJ
    Nat Clin Pract Nephrol; 2007 Sep; 3(9):486-92. PubMed ID: 17717561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The return of the biotech scorecard.
    Jacobs T
    Nat Biotechnol; 2006 Jul; 24(7):768. PubMed ID: 16841056
    [No Abstract]   [Full Text] [Related]  

  • 35. Breakthrough of the year. The Poincaré conjecture--proved.
    Mackenzie D
    Science; 2006 Dec; 314(5807):1848-9. PubMed ID: 17185565
    [No Abstract]   [Full Text] [Related]  

  • 36. The balanced scorecard as a strategic management tool: its application in the regional public health system in Campania.
    Impagliazzo C; Ippolito A; Zoccoli P
    Health Care Manag (Frederick); 2009; 28(1):44-54. PubMed ID: 19225335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief.
    Zeppetella G
    J Pain Symptom Manage; 2008 May; 35(5):563-7. PubMed ID: 18258412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling of the adsorption breakthrough behaviors of Pb2+ in a fixed bed of ETS-10 adsorbent.
    Lv L; Zhang Y; Wang K; Ray AK; Zhao XS
    J Colloid Interface Sci; 2008 Sep; 325(1):57-63. PubMed ID: 18538334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A scorecard for sterile processing metrics.
    OR Manager; 2008 Jul; 24(7):15-6. PubMed ID: 18700491
    [No Abstract]   [Full Text] [Related]  

  • 40. Breakthrough of the year.
    Kennedy D
    Science; 2006 Dec; 314(5807):1841. PubMed ID: 17185564
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.